BILL ANALYSIS

HR10015

BULLISH

To amend the Internal Revenue Code of 1986 to modify health savings accounts, to amend the Public Health Service Act to provide for hospital and insurer price transparency, and for other purposes.

HR10015 (To amend the Internal Revenue Code of 1986 to modify health savings accounts, to amend the Public Health Service Act to provide for hospital and insurer price transparency, and for other purposes.) has been assessed with a bullish outlook for investors. The primary sectors impacted are Healthcare and Finance. View the full bill text on Congress.gov.

bullish

Market Sentiment

4/10

Impact Score

Sectors Impacted

Key Takeaways for Investors

HR10015 is a multi-committee bill with no cosponsors, indicating low momentum.

HSA expansion benefits pure-play HealthEquity ($HQY) most directly.

Price transparency mandate is a headwind for hospital chains like HCA ($HCA).

UnitedHealth ($UNH) has offsetting exposure: HSA gains vs. insurance margin compression.

No convergence with other legislative or executive actions strengthens the bill's isolation.

How HR10015 Affects the Market

The bill is early stage and unlikely to pass in its current form. However, if it gains traction, HealthEquity ($HQY) could see a 5-10% revenue uplift from expanded HSA rules. Hospital stocks (, $THC, $UHS) may face negative sentiment due to transparency mandates, but the actual earnings impact is years away. Insurers (, $CVS, $CI) have mixed exposure and are more likely to adapt via data analytics. The market has not yet priced this bill—no price movement data is available.

Bill Details

Metric	Value
Bill Number	HR10015
Market Sentiment	bullish
Event Date	August 3, 2026
Affected Sectors	Healthcare, Finance
Source	View on Congress.gov →

Summary

HR10015, introduced by Rep. Burlison, proposes HSA rule changes and a hospital/insurer price transparency mandate. The bill is in early committee stage with no cosponsors, making passage uncertain. Pure-play HSA administrator HealthEquity ($HQY) stands to benefit from expanded HSA rules, while hospital chains like HCA face potential margin pressure from price transparency. Insurers like UnitedHealth ($UNH) have a mixed exposure.

Full AI Market Analysis

1) What happened: On August 3, 2026, Rep. Eric Burlison (R-MO) introduced HR10015, which would modify health savings account provisions in the Internal Revenue Code and impose hospital and insurer price transparency requirements under the Public Health Service Act. The bill was referred to eight committees, indicating broad jurisdictional scope but no legislative momentum yet—no cosponsors and no scheduled hearings. 2) The money trail: The bill authorizes no direct federal spending. Its impact flows through regulatory changes: expanding HSA contribution limits or eligibility would increase tax-advantaged healthcare savings, shifting revenue to HSA administrators and insurers offering qualified plans. The price transparency mandate requires hospitals and insurers to publicly disclose negotiated rates, which could reduce healthcare costs but does not create a new government program. No appropriation is needed. 3) Convergence: No concurrent presidential actions or related bills directly share objectives with this legislation. The recent presidential actions on critical minerals and aluminum are unrelated policy domains. This bill is isolated in the current legislative environment. 4) Structural winners and losers: Pure-play HSA custodian HealthEquity ($HQY) is the clearest winner—expanded HSA rules directly increase its account base and fee revenue. UnitedHealth has a mixed position: its Optum Bank benefits from HSA growth, but its insurance segment may face slightly lower medical cost trends from price transparency. Hospital operators like HCA are the most exposed to downside from forced price disclosure, which could compress margins. Smaller hospital chains and community hospitals may be more vulnerable than large-scale operators. 5) Timeline: The bill is at the earliest stage—referred to committees. For it to become law, it must pass through at least one committee, then the full House, then the Senate, and be signed by the President. Given the lack of cosponsors and the midterm election year (2026), passage is unlikely in the current session.